Over the past few decades, engineers have developed various devices that can create holograms, three-dimensional (3D) or ...

A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD; U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment; Notic ...

The IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASDA prespecified analysis in ...

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics. Strengthens strategic ...

FutureG Office is investing in cutting-edge, next-gen techIt has handed $28m in funding to Cohere Technologies for the ...

CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate ...

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPDU.S. patent to expire in March 2043, including 1,095 days of Patent Term AdjustmentNotice of allowance also recei ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced, that ...

Shares in the AI-enabled heart imager have vaulted up to 50%, on the back of a $10-20 million investment from radiology giant ...

Multi-Waveform Wireless Prototype Will Deliver Operational Aerial Surveillance and Response ISAC is a mission-first ...

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA ...